The experimental drug, solengepras, demonstrated significant efficacy in addressing daily living challenges that often plague Parkinson’s patients. Beyond the measured increase in "on" time—periods where medication effectively controls symptoms—participants reported noticeable improvements in motor function and a reduction in issues like excessive salivation and daytime sleepiness.
Parkinson's drug solengepras nears FDA submission after positive trial
Patients suffering from Parkinson’s disease gained an average of 36 minutes of additional daily movement time during the ARISE clinical trial, prompting developers to seek regulatory approval. The findings, presented at the International Congress of Parkinson’s Disease and Movement Disorders, suggest a distinct approach to managing motor function.
Ron Postuma, chair of the MDS International Congress Scientific Program Committee, noted that the self-reported benefits surpassed what the 36-minute increase in movement time might suggest. This discrepancy indicates that the drug may influence patient quality of life through mechanisms beyond simple motor control. Because solengepras operates differently than existing market alternatives, clinical researchers believe its success could signal a broader shift in how movement disorders are treated, potentially unlocking new pathways for future pharmaceutical innovation.
Comments (0)
No comments yet. Be the first!